Successes and Challenges in an Integrated Tuberculosis/HIV Clinic in a Rural, Resource-Limited Setting: Experiences from Kericho, Kenya

Table 3

(a) TB treatment outcomes according to baseline CD4 category in patients initiating ART following TB treatment in the Kericho District Hospital Integrated TB/HIV clinic (𝑛=684). (b) TB treatment outcomes according to time of ART initiation in patients in the Kericho District Hospital Integrated TB/HIV Clinic (𝑛=870).

(a)

CD4 distributions (cells/mm^3)	TB treatment outcome				Row totals
	Treatment success	Transferred out	Lost to followup	Died
<50	116 (66.3)	18 (10.3)	22 (12.8)	19 (10.7)	175 (28.6)
50–99	101 (68.7)	21 (14.3)	16 (10.9)	9 (6.1)	147 (24.0)
100–199	163 (77.3)	18 (8.5)	27 (12.8)	3 (1.4)	211 (34.5)
200–349	53 (86.9)	4 (6.6)	3 (4.9)	1 (3.1)	61 (10.0)
≥350	16 (88.9)	1 (5.6)	1 (5.6)	0 (0)	18 (2.9)

Notes:
(1) Data presented as number (percentage for row total). Data missing: 10.5% for combination of CD4 distributions and TB treatment outcome.
(2) Treatment Success defined as cure or treatment complete.

(b)

Time of ART	Tb Treatment Outcome				Row totals
	Treatment success	Transferred out	Lost to followup	Died
ART Prior to TB Treatment	122 (75.3)	12 (7.4)	14 (8.6)	14 (8.6)	162 (20.5)
ART Following TB Treatment
<2 weeks	39 (65.0)	5 (8.3)	10 (16.7)	6 (10.0)	60 (7.6)
2 weeks–<2 months	227 (66.8)	50 (14.7)	45 (13.2)	18 (5.3)	340 (43.0)
2–6 months	143 (81.7)	7 (4.0)	15 (8.6)	10 (5.7)	175 (22.2)
>6 months	49 (92.5)	1 (1.6)	2 (3.8)	1 (1.9)	53 (6.7)

Notes:
(1) Data presented as number (percentage of row total). Data missing: 10.1% for combination of time of ART and TB treatment outcome.
(2) Treatment success defined as cure or treatment complete.